Investment in stem cell therapy is a top strategic priority in Qatar’s healthcare sector. Stem cell therapy has the potential to treat diverse conditions, such as musculoskeletal disorders, neurological issues, autoimmune diseases, cardiovascular problems, and even cosmetic surgeries.
In line with this goal, Estithmar Holding QPSC, through its subsidiary Elegancia Healthcare, has initiated a groundbreaking partnership with the Korean-based EHL Bio R&D Institute to introduce cutting-edge stem cell therapy at the upcoming launch of the Korean Medical Center (KMC) in Doha, Qatar.
EHL Bio R&D Institute is globally renowned for its revolutionary work in stem cell innovation and regenerative medicine. This will make KMC the exclusive provider of EHL Bio’s advanced stem cell technologies nationwide.
After completing the necessary regulatory procedures, KMC will commence stem cell therapy services, joining forces with top medical and research institutions from South Korea. This strategic alliance is poised to elevate KMC as a premier regional healthcare hub, offering a comprehensive range of specialised medical services in Qatar and the wider GCC region. Located in the heart of Lusail City, the expansive 30,000-square-metre facility underscores a commitment to patient-centric care and sets new standards in healthcare excellence.
South Korea’s reputation in stem cell therapy
South Korea’s prominence in medical tourism, particularly in stem cell transplantation, comes from its dedication to research and new insights. This makes it an attractive destination for patients seeking the best treatments.
The country boasts a robust regulatory framework for stem cell therapy, including critical laws such as The Bioethics and Safety Act, which sets forth guidelines for the ethical conduct of stem cell research, ensuring alignment with international ethical standards. Additionally, the Pharmaceutical Affairs Act oversees stem cell therapies’ approval process and quality control.
South Korea’s diligence in upholding ethical standards, patient safety, and fostering scientific innovation positions it as a global leader in stem cell therapy.
Qatar’s stem cell therapy market
The National Center for Cancer Care and Research (NCCCR) of Hamad Medical Corporation is leading the charge in stem cell therapy in Qatar. The Blood and Marrow Transplant Programme (BMT Programme), spearheaded by Dr. Javid Gaziev, Senior Consultant and Chairman of the Haematology and BMT Department at NCCCR, stands as the sole Adult Haematopoietic Stem Cell Transplant Programme in the country, delivering comprehensive care and remarkable advancements in haematopoietic cell transplantation.
With an interdisciplinary team of experts, including transplant physicians, nurses, and laboratory specialists, the programme has had great success, saving hundreds of lives and representing significant progress in cancer care. Furthermore, NCCCR’s Cell Therapy Laboratory employs state-of-the-art equipment for stem cell graft manipulations, which is essential in facilitating stem cell transplantation procedures.
Another notable institution in Qatar’s stem cell landscape is Sidra Medicine, which houses the Advanced Cell Therapy Core (ACTC). Led by Dr. Chiara Cugno, a seasoned medical doctor with board certification in Pediatrics and Paediatric Haematology/Oncology, the ACTC team is dedicated to advancing cellular therapy through personalised patient care. This extensive approach covers conducting research and creating treatment options in various fields, including Haematopoietic Stem Cell Transplantation, Cell Therapy, Regenerative Medicine, and Gene Therapy, offering novel solutions for diseases affecting children.
These facilities epitomise Qatar’s mission to advance stem cell therapy and become a leading healthcare destination in the region.
About MTM Global
MTM Global is a UK-based international healthcare consultancy and online travel agency specializing in premier health tourism.
For all corporate and media inquiries, click here.
